---
title: "(RXRX.US) vs. XtalPi (2228.HK) by Qwen app"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/36428624.md"
description: "$Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals (RXRX.US) vs. XtalPi (2228.HK)$XTALPI(02228.HK) In-depth competitive benchmarking analysis: Comparison of technological pathways, business strategies, and investment value between the two leading AI-driven drug discovery platforms globally. I. Core Positioning & Strategic Vision Comparison DimensionRecursion Pharmaceuticals (RXRX) Xta..."
datetime: "2025-11-17T11:36:35.000Z"
locales:
  - [en](https://longbridge.com/en/topics/36428624.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/36428624.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/36428624.md)
author: "[老板的老板 AI Exec](https://longbridge.com/en/profiles/123.md)"
---

# (RXRX.US) vs. XtalPi (2228.HK) by Qwen app

# $Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals (RXRX.US) vs. XtalPi (2228.HK)$XTALPI(02228.HK) 

## In-depth Competitive Benchmarking: A Comparative Analysis of Two AI-Driven Drug Discovery Platforms in Terms of Technology, Business Strategy, and Investment Value

* * *

### 1\. Core Positioning and Strategic Vision Comparison

Dimension

**Recursion Pharmaceuticals (RXRX)**

**XtalPi (2228.HK)**

**Company Positioning**

**TechBio platform-driven biopharma**: Internal pipeline driven by proprietary AI platform + external technology licensing

**AI-powered CRO/CDMO platform**: Focuses on providing AI-driven R&D outsourcing services to pharmaceutical companies, **with no self-developed clinical pipeline**

**Strategic Vision**

"Redefining drug discovery with AI," aiming to become the **operating system provider** for next-gen pharma (Recursion OS = OS for drug discovery) \[\[20,27\]\]

"Accelerating global drug R&D with AI," striving to be the **preferred intelligent R&D partner** for global pharma, building "end-to-end AI + wet lab" infrastructure \[\[4\]\]

**Core Logic**

**Risk-sharing, value-sharing**: Deep co-development with pharma partners → shared milestones → shared sales royalties (e.g., 40 targets in Roche collaboration)

**Risk-isolated, fee-for-service**: Project-based service fees + milestone payments (e.g., Novartis, J&J collaborations), no clinical failure risk

**Business Model**

**Dual-engine**:  
• Internal pipeline (high-risk, high-reward)  
• External collaborations (cash flow + validation)

**Single-engine**:  
• AI + wet lab service output (stable cash flow)  
• Minimal exploratory in-house projects (no disclosed clinical progress) \[\[5,8\]\]

✅ **Key Difference**:  
RXRX is a "**drug creator + platform provider**," betting on its platform's ability to produce "blockbuster drugs";  
XtalPi is an "**enabler + service provider**," betting on the **structural growth of outsourcing demand** driven by the paradigm shift in pharma R&D.  
→ The former is a **capital-intensive, high-risk, ultra-high-ceiling** paradigm disruptor; the latter is a **lighter-asset, risk-controlled, more predictable** paradigm beneficiary.

* * *

### 2\. Technology Framework and Core Capabilities Deep Dive

#### 2.1 Data Assets: Breadth vs. Depth

Metric

RXRX

XtalPi

**Data Scale**

\>65PB proprietary data, including **3B+ cell images** (RxRx3), transcriptomics, proteomics, clinical data \[\[21,27\]\]

Total volume undisclosed; per prospectus, generated \*\*\>2B molecular conformations**,** \>1M experimental samples**, covering** \>500 targets\*\* \[\[4,8\]\]

**Data Sources**

• 2.2M weekly wet lab experiments via automation  
• Partnerships: Tempus (real-world data), Helix (genomics), HealthVerity (clinical) \[\[20,43\]\]

• Global pharma partner project data (anonymized sharing)  
• In-house smart labs (Shenzhen, Boston)  
• Enhanced public databases \[\[4,6\]\]

**Data Uniqueness**

**World-leading phenomics**: Cell imaging data as the core moat for training its vision AI models \[\[26\]\]

**Globally 领先的物理化学建模数据**: Especially in **crystal structure prediction (CCP)** and **free energy calculation (FEP)** \[\[4,8\]\]

🔹 **Technical Focus Difference**:

-   **RXRX**: Excels in **phenotype-driven discovery**—reverse-engineering targets/mechanisms from cell images, suited for complex diseases (e.g., neurodegeneration, rare diseases).
-   **XtalPi**: Excels in **structure-driven design**—rationally designing molecules from target protein structures, suited for known target optimization (e.g., kinase inhibitors, GPCR modulators).

#### 2.2 AI Models and Compute Infrastructure

Dimension

RXRX

XtalPi

**Core Models**

• **Phenom-2** (phenotype foundation model)  
• **Boltz-2** (protein structure + binding affinity joint prediction, **open-sourced**)  
• **LOWE** (AI Agent workflow orchestration) \[\[27,28\]\]

• **XtalBrain** (umbrella AI drug discovery platform)  
• **XtalFold** (protein structure prediction，对标 AlphaFold)  
• **XtalDock** (molecular docking), **XtalMD** (dynamics simulation) \[\[4,8\]\]

**Open-Source Strategy**

**Proactive**: Boltz-2 has tens of thousands of GitHub downloads, boosting tech influence and ecosystem stickiness \[\[27\]\]

**Closed**: Core tech not open-sourced; some tools (e.g., XtalFold) offered as API to partners \[\[8\]\]

**Compute Deployment**

• In-house supercomputer **BioHive-2** (TOP500 #35)  
• Expanding BioHive-1 with **500+ NVIDIA H100 GPUs** \[\[13,43\]\]

• Deep partnerships with **AWS, Huawei Cloud, Alibaba Cloud**  
• In-house clusters focus on **high-precision physics calculations** (FEP, QM/MM) \[\[4,6\]\]

**Lab Automation**

• Highly integrated: Robotics +CV+AI closed loop, 2.2M weekly wet experiments \[\[20\]\]

• "Smart lab" network: Shenzhen HQ + Boston center, enabling **high-throughput synthesis, purification, testing integration** \[\[6\]\]

✅ **Key Conclusion**:

-   **RXRX** has a more mature **end-to-end data flywheel**—from experiments → data → training → new experiments;
-   **XtalPi** leads in **physics modeling precision** and **scalable service architecture**, as it serves multiple clients requiring model generalization and stability.

* * *

### 3\. Commercial Progress and Financial Health Comparison

#### 3.1 Partner Ecosystem and Client Quality

Company

Top Partners

Collaboration Depth

Cumulative Monetization (Last 3Y)

**RXRX**

Roche ($150M upfront), Sanofi ($130M+), Bayer, Merck KGaA, BMS \[\[7,15,40\]\]

**Co-R&D + Shared IP**: Joint target selection → shared IP → milestones → sales splits

\>**$500M** (as of 2025Q3) \[\[15\]\]

**XtalPi**

**Novartis** (multi-year), **J&J**, **Pfizer**, **AstraZeneca**, **GSK**, **Pfizer China** \[\[4,8\]\]  
• Domestic: **Hengrui, CSPC, Hansoh, BeiGene**

**Fee-for-Service**: Project fees → milestone payments  
• Added 21 clients in 2024, top 5 client concentration ↓ to 34.9% \[\[8\]\]

\>**$200M** cumulative contracts (2021–2024)  
• 2024 revenue **¥1.28B RMB** (~$176M), +131% YoY \[\[8\]\]

🔍 **Insight**:

-   RXRX’s deals are **higher-value per transaction** (e.g., Roche’s $150M upfront) but more concentrated (top 2 clients ~70%);
-   XtalPi’s client base is **broader and more diversified**, especially with 7/10 global pharma giants, reflecting service model adaptability and stickiness.

#### 3.2 Financial Performance and Sustainability (2024 Full Year / 2025 H1)

Metric

RXRX (USD)

XtalPi (RMB)

**Revenue**

$58.8M (2024) \[\[12\]\]  
$46.2M (2025 H1) \[\[15,17\]\]

¥1.28B (2024) ≈ **$176M** \[\[8\]\]  
¥0.78B (2025 H1) ≈ **$108M** (+52% YoY) \[\[9\]\]

**Gross Margin**

N/A (no product sales)

**72.5%** (2024) → **75.1%** (2025 H1) \[\[8,9\]\]

**Net Loss**

\-$463.7M (2024) \[\[12\]\]  
\-$373.9M (2025 H1)

**First profit**: 2024 net profit **¥32.6M** (~$4.5M), 2025 H1 **¥88.3M** (~$12.2M) \[\[8,9\]\]

**Cash Reserves**

$667M (2025 Q3) \[\[15\]\]

¥2.9B RMB ≈ **$400M** (2025 Q2) \[\[9\]\]

**Cash Flow**

Negative operating cash flow, relies on financing

**Positive operating cash flow**: 2024 ¥285M, 2025 H1 ¥192M \[\[8,9\]\]

✅ **Stark Contrast**:  
**XtalPi achieved profitability and positive operating cash flow in 2024**—the **first global AI drug discovery firm** to hit this milestone \[\[8\]\], proving its **self-sustaining business model**.  
RXRX remains in **heavy investment mode**, with value hinging on future clinical success or milestone payouts.

* * *

### 4\. Pipeline and R&D Output: In-House vs. Enabling

Dimension

RXRX

XtalPi

**In-House Pipeline**

• 5 clinical/preclinical programs (REC-617, REC-4881, etc.)  
• REC-617 in Phase 1/2 with early efficacy signals \[\[15\]\]

• **No disclosed clinical pipeline**  
• Few exploratory projects (e.g., 2023 KRASG12D collab with Hansoh), **not leading clinical development** \[\[5\]\]

**Enabled Output**

• Supporting Roche on 40+ targets  
• Delivered multiple "phenomaps" triggering milestones \[\[53\]\]

• Cumulative **46 preclinical candidates (PCCs) delivered** by 2024  
• **12 advanced to clinical stages** (Phase I), incl. Novartis, J&J programs \[\[4,8\]\]

**Cycle Time**

In-house: ~18 months to PCC (vs. industry 42 months) \[\[27\]\]

Client projects: Avg. **12–18 months** to PCC \[\[4\]\]

📊 **Key Data**:  
XtalPi’s **12 clinical-stage molecules** are the strongest validation of its tech—these are **funded and clinically led by clients**, so XtalPi bears **zero clinical risk** while collecting milestone payments.

* * *

### 5\. Risks and Challenges

Risk Type

RXRX

XtalPi

**Technology**

• Phenotype→target mechanism interpretation challenges ("black box" critique)  
• AI model generalization unproven at scale

• Physics models limited for complex targets (e.g., protein-protein interactions)  
• Service homogenization (competitors like Insilico, InnoCare)

**Business**

• High reliance on few key clients (Roche ~45% revenue)  
• Clinical failure = stock crash

• Client budget cuts (e.g., Biotech winter)  
• Major CROs (e.g., WuXi) accelerating AI

**Financial**

• High burn rate ($300M+/year), needs refinancing post-2027  
• Profitability distant (est. 2030+)

• Small profit scale (2024 net profit just ¥32M)  
• Sustained R&D spend to maintain lead

**Geopolitical**

Low (U.S. firm, global clients)

Medium (HQ in Shenzhen, Boston R&D center; potential U.S.-China tech decoupling scrutiny) \[\[8\]\]

* * *

### 6\. Investment Value: Allocation Logic for Different Risk Appetites

Dimension

**RXRX (High-Risk, High-Reward)**

**XtalPi (Moderate-Risk, Steady Growth)**

**Ideal Investor**

• Long-term tech believers (e.g., ARK)  
• Aggressive growth investors tolerating \>50% swings

• Growth + value balancers  
• Structural AI-enabling opportunity seekers

**Core Thesis**

Bet: Platform can produce **1–2 $5B+ FIC/BIC drugs**，市值对标 Biogen ($25B) or Seagen ($47B acquisition)

Bet: \*\*AI R&D service penetration grows from <5% to \>30%\*\*, gaining share，对标 Charles River ($30B) or WuXi Biologics ($15B)

**Catalysts**

• 2025Q4: REC-4881 FAP data  
• 2026H1: REC-617 ovarian cancer update  
• New $100M+ deal announcement

• 2025Q4: Raised full-year profit guidance  
• 2026H1: First partner molecule enters Phase II  
• FDA "AI/ML-Based SaMD" designation

**Valuation**

Current ~$1.8B; potential $8–12B if REC-617 Phase 2 succeeds

HK market cap ~HK$12.5B (~$1.6B); 2025E P/E ≈ 40x (¥300M profit forecast)

* * *

### 7\. Conclusion: Not Substitutes, but Complements

**RXRX and XtalPi aren’t direct competitors but "rainmakers" and "cultivators" in the AI pharma ecosystem**:

-   RXRX seeks to **break the old paradigm**, building drugs from scratch with AI;
-   XtalPi aims to **optimize the old paradigm**, boosting efficiency with AI.  
    → Differing tech paths (phenotype- vs. structure-driven), contrasting biz models (co-R&D vs. services), distinct risk/reward profiles.

**XtalPi has validated PMF and turned profitable first, with stronger anti-cyclicality**;  
**RXRX is in the critical "tech→value" transition，成败取决于未来 2–3 年的临床数据**.

**Your Playbook**:

-   If chasing **high-multiple, disruptive returns** and tolerate drawdowns → **Allocate to RXRX, focus on 2025 REC-4881 data**;
-   If preferring **steady growth, tech certainty + profit visibility** → **Allocate to XtalPi, now in earnings inflection as the "AI pharma first mover"**;
-   **Optimal**: **Blend both** to capture the dual beta of "paradigm breaking" and "paradigm enabling."

> **Final Insight**:  
> When Roche partners with RXRX to explore 40 new targets while collaborating with XtalPi to optimize known ones—  
> it shows: **The future of drug R&D needs both RXRX’s "explorers" and XtalPi’s "engineers."**  
> Together, they complete the AI pharma landscape.

* * *

**Data Sources & Timeliness**:

-   RXRX: 2024 annual report, 2025 Q1–Q3 filings, investor days (2024.11, 2025.11)
-   XtalPi: 2024 annual report, 2025 interim report, HK prospectus updates, mgmt. roadshows (2025.8–10)
-   All financials converted at Nov 2025 rates (1 USD ≈ 7.25 RMB)
-   Clinical updates as of Nov 17, 2025

### Related Stocks

- [09988.HK](https://longbridge.com/en/quote/09988.HK.md)
- [RXRX.US](https://longbridge.com/en/quote/RXRX.US.md)
- [02228.HK](https://longbridge.com/en/quote/02228.HK.md)
- [CDMO.US](https://longbridge.com/en/quote/CDMO.US.md)
- [GPCR.US](https://longbridge.com/en/quote/GPCR.US.md)
- [600662.CN](https://longbridge.com/en/quote/600662.CN.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [FEP.US](https://longbridge.com/en/quote/FEP.US.md)
- [API.US](https://longbridge.com/en/quote/API.US.md)
- [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md)
- [BABA.US](https://longbridge.com/en/quote/BABA.US.md)
- [89988.HK](https://longbridge.com/en/quote/89988.HK.md)
- [KBAB.US](https://longbridge.com/en/quote/KBAB.US.md)
- [BABO.US](https://longbridge.com/en/quote/BABO.US.md)
- [BABX.US](https://longbridge.com/en/quote/BABX.US.md)
- [NVDL.US](https://longbridge.com/en/quote/NVDL.US.md)
- [07788.HK](https://longbridge.com/en/quote/07788.HK.md)
- [07388.HK](https://longbridge.com/en/quote/07388.HK.md)
- [NVDY.US](https://longbridge.com/en/quote/NVDY.US.md)
- [NVDD.US](https://longbridge.com/en/quote/NVDD.US.md)
- [HBBD.SG](https://longbridge.com/en/quote/HBBD.SG.md)

## Comments (8)

- **Qrion · 2025-11-17T15:25:59.000Z**: Boss, go to sleep quickly. With this market situation, you won't be able to sleep if you don't go now.
- **铁棍山药 · 2025-11-17T12:51:31.000Z**: Thank you for your support of Qianwen
- **余哥稳又富 · 2025-11-17T12:28:36.000Z**: Will Boss' Boss 88888 shares be replenished after the sale?
- **满仓pltr长持 · 2025-11-17T11:42:07.000Z**: I bought this stock a long time ago, and the holding experience was not very good. Personally, I feel that if the stock price starts with 3, the safety margin would be higher.
  - **吕子乔c** (2025-11-17T11:51:57.000Z): I think so too
  - **老板的老板 AI Exec** (2025-11-17T11:53:33.000Z): Currently, I try to buy as much as I can within my ability when the price is below 5 yuan, and hold it for two to three years. Let's see if there will be a miracle.
  - **Jenny W** (2025-12-08T15:28:23.000Z): Awesome, master, it's 77 now
- **陆家嘴老毛 · 2025-11-17T11:39:41.000Z · 👍 1**: Learned something, the boss is really amazing